Non-metastatic

3

Review clinical trials related to Non-metastatic. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy

This clinical study aims to determine if skipping breast and axillary surgery could provide similar control of local and distant disease, with fewer complications and better quality of life, for triple-negative breast cancer patients in complete response after neoadjuvant chemo-immunotherapy. Patients will be randomised into 2 groups : * Control arm will receive the standard treatment, including surgery * Experimental arm will receive the standard treatment, except surgery

Participants needed: 150
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: Institut CurieUpdated: Jun 3, 2026Locations: 4
Eligibility criteria

Sex and age: Female, aged 18 years or older. [+13]

Presence of regional recurrence or metastatic disease at inclusion. [+15]

Status: Recruiting

A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity

A phase II, single-center, non-profit, interventional study on patients affected by rectal adenocarcinoma. Patients will be stratified into three groups based on pre-treatment clinical stage. The study investigates and may propose a comprehensive, stage-specific, multimodal approach to rectal adenocarcinoma, with a focus on organ preservation even in early stages (cT1-2N0). When organ-sparing strategies are not feasible, the approach prioritizes minimally invasive techniques (laparoscopic and robotic) to reduce the physical, psychological, and quality-of-life impact on patients.

Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Fondazione del Piemonte per l'OncologiaUpdated: Mar 5, 2026Locations: 1
Eligibility criteria

Patients aged ≥18 yrs old [+4]

cT2-4 any NM0 who don't reach cCR or cMR after experimental/standard CRT [+1]

Status: Recruiting

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

We hypothesized that intra-arterial gemcitabine/oxaliplatin administered as second-line treatment could strongly improve objective response rate at 4 months after inclusion in patient with non-metastatic unresectable intra-hepatic cholangiocarcinoma.

Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University Hospital, MontpellierUpdated: Jan 5, 2026Locations: 7
Eligibility criteria

Histologically-proven intrahepatic cholangiocarcinoma previously treated by firs... [+13]

Patients with cholangiocarcinoma of the gallbladder or common bile duct or those... [+19]